GOLFMK8
GOLFMK7
GOLFMK6
GOLFMKV

The COVID19 SCAMdemic...Gretafan Doxxes Zrick And Plays The Victim

StorableComa

Autocross Champion
Location
Long Beach, USA
Car(s)
17 GSW S
HOW DID THEY HAVE COVID19 TESTS IN 2018?? CAN YOU SAY SCAMDEMIC?
View attachment 187013
https://www.reuters.com/article/uk-...s-werepurchasedin-2017-and-2018-idUSKBN26025U

Covid is a long running strain of virus that we've known about for some time.

"
The World Bank told Reuters that these products and product codes predate COVID. They have been used since 2017 - not in relation to COVID-19 but labelled “in much more technical terms that did not mention COVID”.

In April 2020, the products were relabelled amid the pandemic and the WITS updated its product descriptions accordingly, including those attached to the data from 2017 and 2018, even if the products had not been used in relation to COVID-19 at the time.

The World Bank said, “In April, given the newfound importance of these products in diagnosing and treating COVID-19, the WHO and the World Customs issued a list ( here , here ) of these key products to make it easier to track them—assigning COVID-related descriptions/labels to each of them. For the same reason (to facilitate easier tracking), the WITS team created a special section using this list (as well as the new WHO/WCO labels/descriptions).”

"
 

brat_burner

Autocross Champion
Location
DFW
Car(s)
VW
10F7B596-97E5-4724-B5C7-2BF44C14C937.gif
 

oddspyke

Autocross Champion
Location
Middletown, DE
Car(s)
2016 GTI, 2018 ZL1
Oh great now he will have to make 2 pages of the same 4 memes to try to bury this.
Haha, you noticed that last time I tried to engage him too? I really enjoyed that after 100+ pages of claiming to have researched all this and having a background in the health field he accidentally betrayed that he didn't know how vaccines work or what a virus is. Maybe I just went to a good school, but those were covered in high school biology and health classes.
 

StorableComa

Autocross Champion
Location
Long Beach, USA
Car(s)
17 GSW S
Haha, you noticed that last time I tried to engage him too? I really enjoyed that after 100+ pages of claiming to have researched all this and having a background in the health field he accidentally betrayed that he didn't know how vaccines work or what a virus is. Maybe I just went to a good school, but those were covered in high school biology and health classes.
Biology is an elective course and not required to graduate in most places. Hence why Common knowledge can never really be common, we all are not given the same information.
 

zrickety

The Fixer
Location
Unknown
Car(s)
09 GTI
Haha, you noticed that last time I tried to engage him too? I really enjoyed that after 100+ pages of claiming to have researched all this and having a background in the health field he accidentally betrayed that he didn't know how vaccines work or what a virus is. Maybe I just went to a good school, but those were covered in high school biology and health classes.
Oh I know how they are SUPPOSED to work and what a virus is. But apparently the CDC is still 'learning'? How does THAT work?!
 

StorableComa

Autocross Champion
Location
Long Beach, USA
Car(s)
17 GSW S
If someone could explain to me why we are locking down the world for a virus with 99.5+% survival for people under 70, I'm all ears.
HOW HAS THE NEW CORONAVIRUS SPREAD ACROSS THE WORLD SO FAST?
Viruses have varying abilities to infect people. For COVID-19, each person with the virus can go on to infect around 2.5 people. If each of those people go about their day as normal, and infect another 2.5 people, within a month, 406 people would be infected just from that first infection.

COVID-19 is more infectious than other coronaviruses such as SARS or MERS-CoV. The “case fatality rate” (CFR), or risk of dying from the new coronavirus, is about 4.4%, (although this risk varies by geography, and also can change over the course of a pandemic) is also less deadly than SARS (10%) or MERS-CoV (34%). So, if COVID-19 is less deadly than previous epidemic threats, why has it spread so far and wide that it has brought the world to a standstill?

The answer seems to be precisely because the new coronavirus is less deadly – thousands of people with either no symptoms or very mild symptoms have been spreading the virus unaware that they were even infected. This means that before health experts were aware of the problem and started to recommend control measures, the virus had already spread to multiple countries.
 

StorableComa

Autocross Champion
Location
Long Beach, USA
Car(s)
17 GSW S
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html
Key Updates for Week 38, ending September 19, 2020
Nationally, indicators that track COVID-19 activity continued to decline or remain stable (change of ≤0.1%); however, three regions reported an increase in the percentage of specimens testing positive for SARS-CoV-2, the virus causing COVID-19, and one of those regions also reported an increase in the percentage of visits for influenza-like illness (ILI) and COVID-like illness (CLI) to emergency departments (EDs). Mortality attributed to COVID-19 declined but remains above the epidemic threshold.
Virus
Public Health, Commercial and Clinical Laboratories
Nationally, the percentage of respiratory specimens testing positive for SARS-CoV-2 decreased from 5.1% during week 37 to 4.8% during week 38. National percentages of specimens testing positive for SARS-CoV-2 by type of laboratory are listed.
  • Public health laboratories – increased from 4.6% during week 37 to 5.1% during week 38
  • Clinical laboratories – decreased from 6.0% during week 37 to 5.4% during week 38
  • Commercial laboratories – decreased from 5.0% during week 37 to 4.6% during week 38
Outpatient and Emergency Department Visits
Outpatient Influenza-Like Illness Network (ILINet) and National Syndromic Surveillance Program (NSSP)
Two surveillance networks are being used to track outpatient or emergency department (ED) visits for illness with symptoms compatible with COVID-19.
  • Nationally, ILI activity remains below baseline for the 23rd consecutive week and is at levels that are typical for this time of year.
  • Nationally, the percentage of visits for ILI reported by ILINet participants and the percentage of visits for COVID-like illness (CLI) reported to NSSP remained stable (change of ≤0.1%) in week 38 compared with week 37.
  • Recent changes in health care seeking behavior, including increasing use of telemedicine, recommendations to limit ED visits to severe illnesses, and increased social distancing, are likely affecting both networks, making it difficult to draw conclusions at this time. Tracking these systems moving forward will give additional insight into illness related to COVID-19.
Severe Disease
Hospitalizations
Cumulative COVID-19-associated hospitalization rates since March 1, 2020, are updated weekly. The overall cumulative COVID-19 hospitalization rate is 174.8 per 100,000, with the highest rates in people aged 65 years and older (472.3 per 100,000) and 50–64 years (261.5 per 100,000).
Mortality
Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 38 is 6.6%. This is currently lower than the percentage during week 37 (9.8%); however, the percentage remains above the epidemic threshold and will likely increase as more death certificates are processed.
All data are preliminary and may change as more reports are received.
A description of the surveillance systems summarized in COVIDView, including methodology and detailed descriptions of each data component,
is available on the surveillance methods page.
Key Points
  • Nationally, since mid-July, there has been an overall decreasing trend in the percentage of specimens testing positive for SARS-CoV-2 and a decreasing or stable (change of ≤0.1%) trend in the percentage of visits for ILI and CLI; however, there has been some regional variation.
  • Using combined data from the three laboratory types, the national percentage of respiratory specimens testing positive for SARS-CoV-2 with a molecular assay decreased from 5.1% during week 37 to 4.8% during week 38.
    • Regionally, the percentage of respiratory specimens testing positive for SARS-CoV-2 increased in Regions 7 (Central), 8 (Mountain) and 10 (Pacific Northwest) and decreased or remained stable in the remaining seven regions.
    • The highest percentage of specimens testing positive for SARS-CoV-2 were seen in Regions 6 (South Central, 8.3%) and 7 (Central, 9.0%).
  • The percentage of outpatient or ED visits to ILINet providers for ILI is below baseline nationally and in all 10 regions of the country.
    • Compared with week 37, the percentage of visits for ILI during week 38 remained stable nationally and decreased or was stable (change of ≤0.1%) in all 10 regions.
  • Nationally, the percentage of visits to EDs for CLI and ILI remained stable (change of ≤0.1%) in week 38 compared with week 37. This is the tenth consecutive week of a declining or stable percentage of visits for CLI and ILI.
    • Region 8 (Mountain) reported an increase in the percentage of visits for both CLI and ILI in week 38 compared to week 37. The remaining nine regions reported a stable (change of ≤0.1%) or decreasing percentage.
  • The overall cumulative COVID-19-associated hospitalization rate was 174.8 per 100,000; rates were highest in people 65 years of age and older (472.3 per 100,000) followed by people 50–64 years (261.5 per 100,000).
    • From the week ending August 1 (MMWR week 31) to the week ending September 19 (MMWR week 38), weekly hospitalization rates declined for all adult age groups. However, over this same time period, weekly rates remained steady for the pediatric age groups. Data for the most recent weeks may change as additional admissions occurring during those weeks are reported.
    • Age-adjusted hospitalization rates for Hispanic or Latino persons and non-Hispanic Black persons were both approximately 4.6 times that of non-Hispanic White persons. The age-adjusted hospitalization rate for non-Hispanic American Indian or Alaska Native persons was approximately 4.5 times that of non-Hispanic White persons.
  • Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 38 was 6.6%, which was lower than the percentage during week 37 (9.8%), but above the epidemic threshold. These percentages will likely increase as more death certificates are processed.
  • All surveillance systems aim to provide the most complete data available. Estimates from previous weeks are subject to change as data are updated with the most complete data available.

U.S. Virologic Surveillance
The number of specimens tested for SARS-CoV-2 using a molecular assay and reported to CDC by public health laboratories and a subset of clinical and commercial laboratories in the United States are summarized below. All laboratories are performing primary diagnostic functions; therefore, the percentage of specimens testing positive across laboratory types can be used to monitor overall trends in COVID-19 activity. As the outbreak progresses, it is possible that different types of laboratories will take on different roles, and the data interpretation may need to change.
Summary of Laboratory Testing Results Reported to CDC
Summary of Laboratory Testing Results Reported to CDC*Week 38
(Sept. 13–Sept. 19, 2020)
Cumulative since March 1, 2020
No. of specimens tested2,029,13051,075,554
Public Health Laboratories294,1536,159,942
Clinical Laboratories175,3085,848,708
Commercial Laboratories1,559,66939,066,904
No. of positive specimens (%)96,477 (4.8%)4,163,115 (8.2%)
Public Health Laboratories15,074 (5.1%)464,343 (7.5%)
Clinical Laboratories9,509 (5.4%)357,369 (6.1%)
Commercial Laboratories71,894 (4.6%)3,341,403 (8.6%)
* Commercial and clinical laboratory data represent select laboratories and do not capture all tests performed in the United States.
Public Health Laboratories
This graph displays the number of respiratory specimens tested by age group and the percent positive for SARS-CoV-2 by age group reported to CDC by U.S. State and Local Public Health Laboratories.
resize iconView Larger
View Data Table
Clinical Laboratories
Clinical Laboratories
resize iconView Larger
View Data Table
Commercial Laboratories
Clinical Laboratories
resize iconView Larger

* Commercial laboratories began testing for SARS-CoV-2 in early March, but the number and geographic distribution of reporting commercial laboratories became stable enough to calculate a weekly percentage of specimens testing positive as of March 29, 2020.
View Data Table
Additional virologic surveillance information:
Surveillance Methods

Outpatient/Emergency Department Illness
Two syndromic surveillance systems are being used to monitor trends in outpatient and emergency department (ED) visits that may be associated with COVID-19 illness. Each system monitors a slightly different syndrome, and together, these systems provide a more comprehensive picture of mild-to-moderate COVID-19 illness than either would individually. Both systems are currently being affected by changes in health care seeking behavior, including increased use of telemedicine, compliance with recommendations to limit ED visits to severe illnesses, and increased social distancing. These changes affect the numbers of people seeking care in the outpatient and ED settings and their reasons for doing so.
ILINet
The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) provides data on visits for influenza-like illness (ILI) (fever [≥100○F] and cough and/or sore throat) to approximately 2,600 primary care providers, emergency departments, and urgent care centers in all 50 states, Puerto Rico, the District of Columbia, and the U.S. Virgin Islands. Mild COVID-19 illness presents with symptoms similar to ILI, so ILINet is being used to track trends of mild-to-moderate COVID-19 illness and allows for comparison with prior influenza seasons.
Nationwide during week 38, 1.0% of patient visits reported through ILINet were due to ILI. This percentage is well below the national baseline of 2.4% and is typical for this time of year compared to previous influenza seasons. Compared with week 37, the percentage of visits for ILI during week 38 slightly increased overall and among those aged 0 to 4 years and 25 to 49 years.
This graph displays the percentage of visits for influenza-like-illness (ILI) by age group reported to CDC by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet).
resize iconView Larger

* Age-group specific percentages should not be compared with the national baseline.
On a regional levelexternal icon, the percentage of outpatient visits for ILI ranged from 0.6% to 1.4% during week 38 and was below the region-specific baseline in all regions. Compared with week 37, the percentage during week 38 decreased slightly in regions 6 (South Central) and 7 (Central) and remained stable (change of ≤0.1%) in the remaining eight regions.
Note: In response to the COVID-19 pandemic, new data sources are being incorporated into ILINet through the summer weeks, when lower levels of influenza and other respiratory virus circulation are typical. Starting in week 21, enrollment of new sites began, leading to increases in the number of patient visits. While all regions remain below baseline levels for ILI, these system changes should be considered when drawing conclusions from these data. Any changes in ILI due to changes in respiratory virus circulation will be highlighted here.
Overall Percentage of Visits for ILI | Age Group ILI Data
ILI Activity Levels
Data collected in ILINet are used to produce a measure of ILI activity for all 50 states, Puerto Rico, the U.S. Virgin Islands, the District of Columbia, and New York City. The mean reported percentage of visits due to ILI for the current week is compared with the mean reported during non-influenza weeks, and the activity levels correspond to the number of standard deviations below, at, or above the mean.
The number of jurisdictions at each activity level during week 38 and changes compared with the previous week are summarized in the table below and shown in the following maps.
ILI Activity Levels
Activity LevelNumber of Jurisdictions
Week 38
(Week ending
September 19, 2020)
Compared with Previous Week
Very High0No Change
High0-1
Moderate1No Change
Low1+1
Minimal49No Change
Insufficient Data3No Change
*Data collected in ILINet may disproportionally represent certain populations within a state and may not accurately depict the full picture of influenza activity for the whole state. Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

National Syndromic Surveillance Program (NSSP): Emergency Department (ED) Visits
NSSP is a collaboration among CDC, federal partners, local, and state health departments and academic and private sector partners to collect, analyze, and share electronic patient encounter data received from multiple health care settings. To track trends of potential COVID-19 visits, visits for COVID-19-like illness (CLI) (fever and cough or shortness of breath or difficulty breathing or presence of a coronavirus diagnosis code) and ILI to a subset of emergency departments in 47 states are being monitored.
Nationwide during week 38, 1.8% of ED visits captured in NSSP were due to CLI and 0.7% were due to ILI. Compared with week 37, the percentage of visits for CLI and the percentage of visits for ILI this week decreased or remained stable (changes of ≤0.1%) nationally and in 9 of 10 HHS regionsexternal icon. Region 8 (Mountain) saw an increase in both CLI and ILI compared with week 37.


Additional information about medically attended outpatient and emergency department visits for ILI and CLI: Surveillance Methods

Hospitalizations
The COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) conducts population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in select counties participating in the Emerging Infections Program (EIP) and the Influenza Hospitalization Surveillance Project (IHSP).
A total of 57,006 laboratory-confirmed COVID-19-associated hospitalizations were reported by sites between March 1, 2020, and September 19, 2020. The overall cumulative hospitalization rate was 174.8 per 100,000 population. Among those aged 0–4 years, 5–17 years, 18–49 years, 50–64 years, and ≥65 years, the highest rate of hospitalization was among adults aged ≥65 years, followed by adults aged 50–64 years and adults aged 18–49 years.

laboratory-confirmed COVID-19-associated hospitalizations

resize iconView Larger

Hospitalization Rates
Age GroupCumulative Rate per 100,000 Population
Overall174.8
0-4 years17.9
5-17 years10.3
18-49 years119.2
18-29 years​
76.6
30-39 years​
119.1
40-49 years​
174.4
50-64 years261.5
65+ years472.3
65-74 years​
354.2
75-84 years​
562.3
85+ years​
850.1

Weekly hospitalization rates among all ages first peaked during the week ending April 18 (MMWR week 16), followed by a second peak during the week ending July 18 (MMWR week 29). From the week ending August 1 (MMWR week 31) to the week ending September 19 (MMWR week 38), weekly hospitalization rates declined for all adult age groups. However, over this same time period, weekly rates remained steady for the pediatric age groups. Data for the most recent weeks may change as additional admissions occurring during those weeks are reported.
Laboratory-Confirmed COVID-19-Associated Hospitalizations

resize iconView Larger

Among the 57,006 laboratory-confirmed COVID-19-associated hospitalizations, 54,074 (94.9%) had information on race and ethnicity, while collection of race and ethnicity was still pending for 2,932 (5.1%) cases. When examining overall age-adjusted rates by race and ethnicity, rates for Hispanic or Latino persons and non-Hispanic Black persons were both approximately 4.6 times the rate among non-Hispanic White persons. The age-adjusted hospitalization rate for non-Hispanic American Indian or Alaska Native persons was approximately 4.5 times that of non-Hispanic White persons.


When examining age-stratified crude hospitalization rates by race and ethnicity, compared with non-Hispanic White persons in the same age group, crude hospitalization rates were 7.5 times higher among Hispanic or Latino persons aged 0–17 years; 8.4 times higher among Hispanic or Latino persons aged 18–49 years; 6.2 times higher among non-Hispanic American Indian or Alaska Native persons aged 50–64 years; and 3.7 times higher among non-Hispanic Black persons aged ≥65 years.
Hospitalization rates per 100,000 population
by age and race and ethnicity — COVID-NET,
March 1, 2020–September 19, 2020
Age Category
Non-Hispanic
American Indian or Alaska Native
Non-Hispanic Black
Hispanic or Latino
Non-Hispanic Asian or Pacific Islander
Non-Hispanic White
Rate1Rate Ratio2,3Rate1Rate Ratio2,3Rate1Rate Ratio2,3Rate1Rate Ratio2,3Rate1Rate Ratio2,3
0—17 years11.73.518.65.624.67.56.31.93.31
18—49 years260.57.8194.75.8279.38.455.41.733.41
50—64 years643.46.2545.05.2595.85.7166.81.6104.41
65+ years715.02.51074.23.7784.52.7319.81.1290.31
Overall rate4 (age-adjusted)349.94.5356.84.6358.54.6104.71.377.71
1 COVID-19-associated hospitalization rates by race and ethnicity are calculated using COVID-NET hospitalizations with known race and ethnicity for the numerator and NCHS bridged-race population estimates for the denominator.
2 For each age category, rate ratios are the ratios between crude hospitalization rates within each racial and ethnic group and the crude hospitalization rate among non-Hispanic white persons in the same age category.
3 The highest rate ratio in each age category is presented in bold.
4 Overall rates are adjusted to account for differences in age distributions within race and ethnicity strata in the COVID-NET catchment area; the age strata used for the adjustment include 0–17, 18–49, 50–64, and 65+ years.
Non-Hispanic Black persons and non-Hispanic White persons represented the highest proportions of hospitalizations reported to COVID-NET, followed by Hispanic or Latino, non-Hispanic Asian or Pacific Islander, and non-Hispanic American Indian or Alaska Native persons. However, some racial and ethnic groups are disproportionately represented among hospitalizations as compared with the overall population of the catchment area. Prevalence ratios were highest among non-Hispanic American Indian or Alaska Native persons, followed by non-Hispanic Black persons and Hispanic or Latino persons.
Comparison of proportions of COVID-19-associated hospitalizations by race and ethnicity, COVID-NET, March 1–September 19, 2020
Non-Hispanic American Indian or Alaska NativeNon-Hispanic BlackHispanic or LatinoNon-Hispanic Asian or Pacific IslanderNon-Hispanic White
Proportion of hospitalized COVID-NET cases11.3%33.0%23.1%5.1%31.8%
Proportion of population in COVID-NET catchment0.7%17.9%14.1%8.9%58.5%
Prevalence ratios21.91.81.60.60.5
1 Persons of multiple races (0.3%) or unknown race and ethnicity (5.4%) are not represented in the table but are included as part of the denominator.
2 Prevalence ratio is calculated as the ratio of the proportion of COVID-NET hospitalizations over the proportion of population in COVID-NET catchment area.
Among 12,151 hospitalized adults with information on underlying medical conditions, 90.4% had at least one reported underlying medical condition. The most commonly reported underlying medical conditions were hypertension, obesity, metabolic disease, and cardiovascular disease. Among 393 hospitalized children with information on underlying conditions, 49.9% had at least one reported underlying medical condition. The most commonly reported underlying medical conditions were obesity, neurologic disease, and asthma.
This graph displays data on lab confirmed hospitalizations with underlying conditions.

resize iconView Larger

Additional data on demographics, signs and symptoms at admission, underlying conditions, interventions, outcomes and discharge diagnoses, stratified by age, sex and race and ethnicity, are available.
Additional hospitalization surveillance information: Surveillance Methods | Additional rate data | Additional demographic and clinical data


Mortality Surveillance
The National Center for Health Statistics (NCHS) collects death certificate data from vital statistics offices for all deaths occurring in the United States. Based on death certificate data available on September 24, 2020, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 38 is 6.6% and, while lower than the percentage during week 37 (9.8%), remains above the epidemic threshold. Percentages for recent weeks will likely increase as more death certificates are processed.
Weekly mortality surveillance data include a combination of machine coded and manually coded causes of death collected from death certificates. Percentages of deaths due to PIC are higher among manually coded records than more rapidly available machine coded records. Due to the additional time needed for manual coding, the initially reported PIC percentages may be lower than percentages calculated from final data.
This graph shows pneumonia and influenza (P&I) mortality data provided to CDC by the National Center for Health Statistics (NCHS) Mortality Reporting System.

resize iconView Larger

*Data during recent weeks are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes.
View Data Table
Additional NCHS mortality surveillance information: Surveillance Methods | Provisional Death Counts for COVID-19
More Information
View Page In:pdf icon 13 Pages, 1 MB

Last Updated Sept. 25, 2020
Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases
homeCases, Data & Surveillance
email_03Get Email Updates
To receive email updates about COVID-19, enter your email address:
Email Address
What's this?
Submit
 
Top